Information on Abzena's Response to COVID-19 - Abzena

Information on Abzena’s Response to COVID-19

This page will remain up to date on Abzena’s response to COVID-19

Last updated 09:30 GMT 25th March 2020

To Our Valued Partner,

As public announcements are made and countries move to “non-life sustaining” business closures, “essential critical infrastructure” and “key workers in a critical sector” definitions, we want to re-assure you that we are continuing to operate at all three Abzena locations.   We continue to monitor these developments and will notify our employees and our valued partners if there is any change in government regulations, orders or decrees that will require change to our business operations.

Abzena designs, develops and manufactures drugs and vaccines to prevent and treat life threatening disease including infectious disease (e.g. viral and bacterial infections), cancer and severe inflammatory conditions (e.g. asthma and COPD). We are in active discussions with a number of developers in applying our services to tackle COVID-19 through expedited drug and vaccine development and support the manufacture and supply of these drugs.

Additionally, we have provided all employees with guidelines in order to ensure their health and safety, including guidance on self-quarantining, social distancing, self-monitoring and heightened cleaning practices.

Please don’t hesitate to contact me, your Business Development contact or fill out our contact form here should you have further questions.

Thank you for your support as we navigate through this global emergency. Our priority is to keep our employees safe and healthy while we continue our operations.

With warm regards,

Kimball Hall
Chief Operating Officer
Abzena

Interested in our services? Get In Touch